Reference List

1. Bray GA, Greenway FL. Current and potential drugs for treatment of obesity. Endocr Rev 1999;20(6):805-75.

2. Flegal KM, Carroll MD, Ogden CL, et al. Prevalence and trends in obesity among US adults, 1999-2000. JAMA 2002;288(14):1723-7.

3. Mokdad AH, Bowman BA, Ford ES, et al. The continuing epidemics of obesity and diabetes in the United States. JAMA 2001;286(10):1195-200.

4. Mokdad AH, Serdula MK, Dietz WH, et al. The continuing epidemic of obesity in the United States. JAMA 2000;284(13):1650-1.

5. Mokdad AH, Serdula MK, Dietz WH, et al. The spread of the obesity epidemic in the United States, 1991-1998. JAMA 1999;282(16):1519-22.

6. Centers for Disease Control and Prevention. Obesity epidemic increases dramatically in the United States. available at URL: http://www.cdc.gov/nccdphp/dnpa/obesityepidemic him. Accessed 6/11/2002.

7. Kuczmarski RJ, Flegal KM, Campbell SM, et al. Increasing prevalence of overweight among US adults. The National Health and Nutrition Examination Surveys, 1960 to 1991. JAMA 1994;272(3):205-11.

8. Katzmarzyk PT. The Canadian obesity epidemic, 1985-1998. CMAI 2002;166(8):1039-40.

9. Katzmarzyk P. T. Obesity in Canadian children. CMAJ 2001;164(11):1563-4; author reply 1564-5.

10. World Health Organization. Controlling the global obesity epidemic. available at URL: http://www.who.int/nut/obs.html. Accessed 6/20/2002.

11. Friedrich MJ. Epidemic of obesity expands its spread to developing countries. JAMA 2002;287(11):1382-6.

12. Must A, Spadano J, Coakley EH, et al. The disease burden associated with overweight and obesity. JAMA 1999;282(16):1523-9.

13. Pi-Sunyer FX. Medical hazards of obesity. Ann Intern Med 1993;119(7 Pt 2):655-60.

14. Ogden CL, Flegal KM, Carroll MD, et al. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA 2002;288(14):1728-32.

15. Eckel RH, Krauss RM. American Heart Association call to action: obesity as a major risk factor for coronary heart disease. AHA Nutrition Committee. Circulation 1998;97(21):2099-100.

16. National Institutes of Health. Clinical Guidelines on the Identification, Evaluation, and Treatment of Overweight and Obesity in Adults--The Evidence Report. Obes Res 1998;6 Suppl 2:51S-209S.

17. Pi-Sunyer FX. A review of long-term studies evaluating the efficacy of weight loss in ameliorating disorders associated with obesity. Clin Ther 1996;18(6):1006-35; discussion 1005.

18. Allison DB, Pi-Sunyer FX. Obesity treatment: examining the premises. Endocr Pract 1995;1:353-364.

19. Calle EE, Rodriguez C, Walker-Thurmond K, et al. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348(17):1625-38.

20. Huang Z, Hankinson SE, Colditz GA, et al. Dual effects of weight and weight gain on breast cancer risk. JAMA 1997;278(17):1407-11.

21. Goldstein DJ . Beneficial health effects of modest weight loss. Int J Obes Relat Metab Disord 1992;16(6):397-415.

22. Knowler WC, Barrett-Connor E, Fowler SE, et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002 ;346(6):393-403.

23. National Library of Medicine/National Institutes of Health. Sibutramine. Medline Plus Drug Information. available at URL: www.nlm.nih.gov/medlineplus/druginfo/medmaster/a697012.html. Accessed 5/14/2004.

24. Croghan, T. Personal Communication, Washington DC, RAND. 2004.

25. National Library of Medicine/ National Institutes of Health. Sertraline. Mediline Plus Drug Information. available at URL: www.nlm.nih.gov/medlineplus/druginfo/medmaster/a697048.html. Accessed 5/4/2004.

26. Nielsen JA, Chapin DS, Johnson JL Jr, et al. Sertraline, a serotonin-uptake inhibitor, reduces food intake and body weight in lean rats and genetically obese mice. Am J Clin Nutr 1992;55(1 Suppl):185S-189S.

27. History of Phentermine. Phentermine. available at URL: http://www.phentermine.com/phentermine_history.htm. Accessed 5/4/2004.

28. RxList.com. Tenuate (Diethylpropion) Description. available at URL: http://www.rxlist.com/cgi/generic3/diethprop.htm. Accessed 5/4/2004.

29. Thompson CenterWatch Clinical Trials Listing Service. Drugs Approved by the FDA: Drug Name Zonegrin (Zonisamide) Capsules. available at URL: www.centerwatch.com/patient/drugs/dru613.html. Accessed 5/4/2004.

30. Woods TM, Eichner SF, Franks AS. Weight gain mitigation with topiramate in mood disorders. Ann Pharmacother 2004;38(5):887-91.

31. Bray GA, Hollander P, Klein S, et al. A 6-Month Randomized, Placebo-Controlled, Dose-Ranging Trial of Topiramate for Weight Loss in Obesity. Obes Res 2003;11(6):722-733.

32. National Library of Medicine/National Institutes of Health. Topiramate. Medline Plus Drug Information. available at URL: www.nlm.nih.gov/medlineplus/druginfo/medmaster/a697012.html. Accessed 5/14/2004.

33. Roche Pharmaceuticals Complete Product Information. Xenical (orlistat). available at URL: www.rocheusa.com/products/xenical/ . Accessed 5/14/2004.

34. Avenell A,Broom J, Aucott L, Brown TJ, Poobalan A, Stearns S, et al. Systematic review of the long-term outcomes of the treatments for obesity and implications for health improvement and the economic consequences for the National Health Service. Health Technol Assess 2003 (In Press).

35. O'Meara S, Riemsma R, Shirran L, et al. A rapid and systematic review of the lcinical effectiveness and cost-effectiveness of orlistat in the management of obesity. Health Technol Assess 2001;5(18):1-81.

36. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: A systematic review. (In Press).

37. Clegg A, Colquitt J, Sidhu MK, Royle P, Loveman E, Walker A. The clinical effectiveness and cost-effectiveness of surgery for people with morbid obesity: a systematic review and economic evaluation. Health Technol Assess 2002;6(12).

38. Colquitt J, Clegg A, Sidhu M, et al. Surgery for morbid obesity (Cochrane Review). Cochrane Database Syst Rev 2003;(2):CD003641.

39. Jadad AR, Moore RA, Carroll D, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17(1):1-12.

40. Moher D, Pham B, Jones A, et al. Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 1998;352(9128):609-613.

41. Stata Statistical Software: Release 7.0 [computer program]. Version 7.0. College Station: Stata Corporation; 2001.

42. Sutton AJ, Jones DR, Abrams KR, et al. Systematic reviews and meta-analysis: a structured review of the methodological literature. J Health Serv Res Policy 1999;4(1):49-55.

43. Anderson JW, Greenway FL, Fujioka K, et al. Bupropion SR enhances weight loss: a 48-week double-blind, placebo- controlled trial. Obes Res 2002;10(7):633-41.

44. Michelson D, Amsterdam JD, Kim Y, Sundell K. Changes in weight during a one-year trial with fluoxetine. 152nd Annual Meeting of the American Psychiatric Association. May 15th - 20th, 1999; Washington, DC, USA. 1999.

45. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7(3):177-188.

46. Hedges LV, Olkin I. Statistical methods for meta-analysis. San Diego, CA: Academic Press, Inc.; 1985.

47. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315(7109):629-634.

48. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50 (4):1088-1101.

49. StatXact 4 for Windows [computer program]. Version 4.0. Cambridge, MA: Cytel Software Corporation; 2000.

50. Miller J.N., Colditz G.A., Mosteller F. How study design affects outcomes of comparisons of therapy: II: surgical. Stats Med. 1989 8:455-466.(Abstract)

51. Moseley J., O'Malley K., Petersen N.J., Brody B.A., Kuykendall D.H., Hollingsworth J.C., et al. A controlled trial of arthroscropic surgery for osteoarthritis of the knee. J Fam Pract. 2002 51:(10)813-(Abstract)

52. Failure of extracranial-intracranial arterial bypass to reduce the risk of ischemic stroke. Results of an international randomized trial. The EC/IC Bypass Study Group. N Engl J Med. 1985 313:(19)1191-200.(Abstract)

53. Arterburn DE, Crane PK, Veenstra DL. The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med 2004;164(9):994-1003.

54. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res 1999;7(2):189-98.

55. Davidson MH, Hauptman J, DiGirolamo M, et al. Weight control and risk factor reduction in obese subjects treated for 2 years with orlistat: a randomized controlled trial. JAMA 1999;281(3):235-42.

56. Hauptman J, Lucas C, Boldrin MN, et al. Orlistat in the long-term treatment of obesity in primary care settings. Arch Fam Med 2000;9(2): 160-7.

57. Hill JO, Hauptman J, Anderson JW, et al. Orlistat, a lipase inhibitor, for weight maintenance after conventional dieting: a 1-y study. Am J Clin Nutr 1999;69(6):1108-16.

58. Hollander PA, Elbein SC, Hirsch IB, et al. Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study. Diabetes Care 1998;21(8):1288-94.

59. Lindahl B, Dinesen B, Eliasson M, et al. High proinsulin concentration precedes acute myocardial infarction in a nondiabetic population. Metabolism 1999;48(9):1197-202.

60. Rossner S, Sjostrom L, Noack R, et al. Weight loss, weight maintenance, and improved cardiovascular risk factors after 2 years treatment with orlistat for obesity. European Orlistat Obesity Study Group. Obes Res 2000;8(1):49-61.

61. Sjostrom L, Rissanen A, Andersen T, et al. Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients. European Multicentre Orlistat Study Group. Lancet 1998;352(9123):167-72.

62. Vidgren HM, Agren JJ, Valve RS, et al. The effect of orlistat on the fatty acid composition of serum lipid fractions in obese subjects. Clin Pharmacol Ther 1999;66(3):315-22.

63. Rissanen P, Vahtera E, Krusius T, et al. Weight change and blood coagulability and fibrinolysis in healthy obese women. Int J Obes Relat Metab Disord 2001;25(2):212-8.

64. Broom I. Randomised trial of the effect of orlistat on body weight and CVD risk profile in overweight and obese patients with co-morbidities. Int J Obes Relat Metab Disord 2001;25(Suppl):S106.

65. Broom I, Hughes E, Dodgson P, et al. on behalf of the Orlistat UK Study Group. The role of orlistat in the treatment of obese patients with mild to moderate hypercholesterolaemia: consequences for coronary risk. Br J Cariol 2002;9(8):460-8.

66. Muls E, Kolanowski J, Scheen A, et al. The effects of orlistat on weight and on serum lipids in obese patients with hypercholesterolemia: a randomized, double-blind, placebo-controlled, multicentre study. Int J Obes Relat Metab Disord 2001;25(11):1713-21.

67. Deerochanawong Chaicharn. Effect of treatment with orlistat in overweight or obese Thai patients with type 2 diabetes. Diabetes 2001;50(Supplement 2):A433.

68. Shi Yi Fan, Zhu Jun Ren. Effect of orlistat on weight loss and glycemic control in overweight Chinese patients with type 2 diabetes. Diabetes 2001;50(Supplement 2):A101-A102.

69. Kelley DE, Bray GA, Pi-Sunyer FX, et al. Clinical efficacy of orlistat therapy in overweight and obese patientswith insulin-treated type 2 diabetes: a 1-year randomized controlledtrial. Diabetes Care 2002;25(6):1033-1041.

70. Karhunen L, Franssila-Kallunki A, Rissanen P, et al. Effect of orlistat treatment on body composition and resting energy expenditure during a two-year weight-reduction programme in obese Finns. Int J Obes Relat Metab Disord 2000;24(12):1567-72.

71. Krempf M, Louvet JP, Allanic H, et al. Weight reduction and long-term maintenance after 18 months treatment with orlistat for obesity. Int J Obes Relat Metab Disord 2003;27(5):591-7.

72. Halpern A, Mancini MC, Suplicy H, et al. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients. Diabetes Obes Metab 2003;5(3):180-8.

73. Lucas CP, Boldrin MN, Reaven GM. Effect of orlistat added to diet (30% of calories from fat) on plasma lipids, glucose, and insulin in obese patients with hypercholesterolemia. Am J Cardiol 2003;91(8):961-4.

74. Bakris G, Calhoun D, Egan B, et al. Orlistat improves blood pressure control in obese subjects with treated but inadequately controlled hypertension. J Hypertens 2002;20(11):2257-67.

75. Hanefeld M, Sachse G. The effects of orlistat on body weight and glycaemic control in overweight patients with type 2 diabetes: a randomized, placebo-controlled trial. Diabetes Obes Metab 2002;4(6):415-23.

76. Miles JM, Leiter L, Hollander P, et al. Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin. Diabetes Care 2002;25(7):1123-8.

77. Rosenfalck AM, Hendel H, Rasmussen MH, et al. Minor long-term changes in weight have beneficial effects on insulin sensitivity and beta-cell function in obese subjects. Diabetes Obes Metab 2002;4 (1):19-28.

78. Naumov VG, Lupanov VP, Dotsenko IuV, et al. [Six-month xenical (orlistat) therapy of patients with stable angina pectoris concomitant with obesity and hyperlipidemia]. Ter Arkh 2002;74(1):47-51.

79. Gotfredsen A, Westergren Hendel H, Andersen T. Influence of orlistat on bone turnover and body composition. Int J Obes Relat Metab Disord 2001;25(8):1154-60.

80. Reaven G, Segal K, Hauptman J, et al. Effect of orlistat-assisted weight loss in decreasing coronary heart disease risk in patients with syndrome X. Am J Cardiol 2001;87(7):827-31.

81. Micic D, Ivkovic-Lazar T, Dragojevic R, et al. Orlistat, a gastrointestinal lipase inhibitor, in therapy of obesity with concomitant hyperlipidemia. Med Pregl 1999;52(9-10):323-33.

82. Derosa G, Mugellini A, Ciccarelli L, et al. Randomized, double-blind, placebo-controlled comparison of the action of orlistat, fluvastatin, or both an anthropometric measurements, blood pressure, and lipid profile in obese patients with hypercholesterolemia prescribed a standardized diet. Clin Ther 2003;25(4):1107-22.

83. Lindgarde F. The effect of orlistat on body weight and coronary heart disease risk profile in obese patients: the Swedish Multimorbidity Study. J Intern Med 2000;248(3):245-54.

84. Broom I, Wilding J, Stott P, et al. Randomised trial of the effect of orlistat on body weight and cardiovascular disease risk profile in obese patients: UK Multimorbidity Study. Int J Clin Pract 2002;56(7):494-9.

85. Haddock CK, Poston WS, Dill PL, et al. Pharmacotherapy for obesity: a quantitative analysis of four decades of published randomized clinical trials. Int J Obes Relat Metab Disord 2002;26 (2):262-73.

86. Kokkinos J, Levine SR. Possible association of ischemic stroke with phentermine. Stroke 1993;24(2):310-3.

87. Kim I, Whitsett TL. Acute vasospasm associated with anorexiant use. J Okla State Med Assoc 1988;81(7):395-8.

88. Breum L, Bjerre U, Bak JF, et al. Long-term effects of fluoxetine on glycemic control in obese patients with non-insulin-dependent diabetes mellitus or glucose intolerance: influence on muscle glycogen synthase and insulin receptor kinase activity. Metabolism 1995;44(12):1570-6.

89. Goldstein DJ, Rampey AHJr, Enas GG, et al. Fluoxetine: a randomized clinical trial in the treatment of obesity. Int J Obes Relat Metab Disord 1994;18(3):129-35.

90. Marcus MD, Wing RR, Ewing L, et al. A double-blind, placebo-controlled trial of fluoxetine plus behavior modification in the treatment of obese binge-eaters and non-binge- eaters. Am J Psychiatry 1990;147(7):876-81.

91. Darga LL, Carroll-Michals L, Botsford SJ, et al. Fluoxetine's effect on weight loss in obese subjects. Am J Clin Nutr 1991;54(2):321-5.

92. O'Kane M, Wiles PG, Wales JK. Fluoxetine in the treatment of obese type 2 diabetic patients. Diabet Med 1994;11(1):105-10.

93. Connolly VM, Gallagher A, Kesson CM. A study of fluoxetine in obese elderly patients with type 2 diabetes. Diabet Med 1995;12(5):416-8.

94. Mendoza Espejo R, Diaz Perez de Madrid J, Buitrago F. [Effectiveness of serotonergic agonists in the treatment of obese patients]. Aten Primaria 1995;16(6):364-6.

95. Gray DS, Fujioka K, Devine W, et al. Fluoxetine treatment of the obese diabetic. Int J Obes Relat Metab Disord 1992;16(3):193-8.

96. Wadden TA, Bartlett SJ, Foster GD, et al. Sertraline and relapse prevention training following treatment by very- low-calorie diet: a controlled clinical trial. Obes Res 1995;3(6):549-57.

97. Anderson James W, Greenway Frank, Fujioka Ken, et al. Buproprion SR significantly enhances weight loss when used with a moderate-intensity lifestyle intervention. Diabetes 2001;50(Supplement 2):A21.

98. Croft H, Houser TL, Jamerson BD, et al. Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks. Clin Ther 2002;24(4):662-72.

99. Jain AK, Kaplan RA, Gadde KM, et al. Bupropion SR vs. placebo for weight loss in obese patients with depressive symptoms. Obes Res 2002;10(10):1049-56.

100. Gilliam FG, Veloso F, Bomhof MA, et al. A dose-comparison trial of topiramate as monotherapy in recently diagnosed partial epilepsy. Neurology 2003;60(2):196-202.

101. Bray G, Klein S, Levy B, Fitchet M, Perry B. Topiramate produces dose-related weight loss in obese patients. Presented at the 62nd American Diabetes Association Scientific Sessions. 2002 (Abstract)

102. Stenlof K, Rossner S, Vercruysse F, Perry B, Fitchet M, Sjostrom L. Safety and efficacy of Topiramate in the treatment of Type II diabetic obese subjects: A randomized, double-blind, placebo-controlled trial. Presented at the 18th International Diabetes Federation Congress. 2003 (Abstract)

103. Stenlof K, Rossner S, Vercruysse F, Perry B, Fitchet M, Sjostrom L. Topiramate decreases weight and blood pressure in obese subjects with Type II diabetes. Presented at the North American Association of rthe Study of Obesity 2003 Annual Scientific Meeting. 2003 (Abstract)

104. Rissanen A, Wilding J, Van Gaal L, Vercruysse F, Perry B, Fitchet M. The effect of Topiramate on body weight and blood pressure in obese subjects: A long-term, randomized, placebo-controlled trial. Presented at the 18th Internation Diabetes Federation Congress. 2003 (Abstract)

105. Pud'homme D, Firchet M, Almeras N, Dumont M, Tremblay A, Despres JP. Six-month Topiramate treatment reduces body weight and blood pressure. Presented at the North American Association for the Study of Obesity 2003 Annual Scientific Meeting. 2003 (Abstract)

106. Tonstad S, Levy B, Perry B, Fitchet M. Topiramate decreases weight and lowers blood pressure in obese subjects with hypertension. Presented at the North American Association for the Study of Obesity 2003 Annual Scientific Meeting. 2003 (Abstract)

107. Caterson I, Astrup A, Zelissen P, Guy-Grand B, Carruba M, Levy B, et al. The long-term effect of Topiramate on body weight maintenance after low-calorie diet-induced wieght loss in obese subjects. Presented at the 18th International Diabetes Federation Congress. 2003 (Abstract)

108. Gadde KM, Franciscy DM, Wagner HR 2nd, et al. Zonisamide for weight loss in obese adults: a randomized controlled trial. JAMA 2003;289(14):1820-5.

109. Sjostrom CD, Peltonen M, Sjostrom L. Blood pressure and pulse pressure during long-term weight loss in the obese: the Swedish Obese Subjects (SOS) Intervention Study. Obes Res 2001;9(3):188-95.

110. Sjostrom CD, Peltonen M, Wedel H, et al. Differentiated long-term effects of intentional weight loss on diabetes and hypertension. Hypertension 2000 ;36(1):20-5.

111. Karason K, Lindroos AK, Stenlof K, et al. Relief of cardiorespiratory symptoms and increased physical activity after surgically induced weight loss: results from the Swedish Obese Subjects study. Arch Intern Med 2000;160(12):1797-802.

112. Karason K, Molgaard H, Wikstrand J, et al. Heart rate variability in obesity and the effect of weight loss. Am J Cardiol 1999;83(8):1242-7.

113. Karason K, Wikstrand J, Sjostrom L, et al. Weight loss and progression of early atherosclerosis in the carotid artery: a four-year controlled study of obese subjects. Int J Obes Relat Metab Disord 1999;23(9):948-56.

114. Karlsson J, Sjostrom L, Sullivan M. Swedish obese subjects (SOS)-an intervention study of obesity. Two-year follow-up of health-related quality of life (HRQL) and eating behavior after gastric surgery for severe obesity. Int J Obes Relat Metab Disord 1998;22(2):113-26.

115. Narbro K, Agren G, Jonsson E, et al. Sick leave and disability pension before and after treatment for obesity: a report from the Swedish Obese Subjects (SOS) study. Int J Obes Relat Metab Disord 1999;23(6):619-24.

116. Sjostrom CD, Lissner L, Wedel H, et al. Reduction in incidence of diabetes, hypertension and lipid disturbances after intentional weight loss induced by bariatric surgery: the SOS Intervention Study. Obes Res 1999;7(5):477-84.

117. Weiner R, Bockhorn H, Rosenthal R, et al. A prospective randomized trial of different laparoscopic gastric banding techniques for morbid obesity. Surgical endoscopy 2001;15(1):63-8.

118. de Wit LT, Mathus-Vliegen L, Hey C, et al. Open versus laparoscopic adjustable silicone gastric banding: a prospective randomized trial for treatment of morbid obesity. Annals of surgery 1999;230(6):800-5.

119. Brolin RE, Kenler H A, Gorman J H, et al. Long-limb gastric bypass in the superobese. A prospective randomized study. Annals of surgery 1992;215(4):387-95.

120. Andersen T, Backer OG, Stokholm K H, et al. Randomized trial of diet and gastroplasty compared with diet alone in morbid obesity. New England journal of medicine 1984;310(6):352-6.

121. Andersen T, Backer OG, Stokholm K H, et al. [Gastroplasty versus very low calorie diet in morbid obesity. Short-term results of a randomized clinical trial]: <Original> Gastroplastik versus ekstrem lavkalorie-diaet (very-low-calorie diet) ved svaer adipositas. Korttidsresultater af en randomiseret klinisk undersogelse. Ugeskrift for laeger 1982;144(6):390-4.

122. Lechner GW, Callender A K. Subtotal gastric exclusion and gastric partitioning: a randomized prospective comparison of one hundred patients. Surgery 1981;90(4):637-44.

123. Quaade F. Jejunoileal bypass for morbid obesity. A bibliographic study and a randomized clinical trial. Surgical clinics of North America 1979;59(6):1055-69.

124. The Danish Obesity Project. Randomised trial of jejunoileal bypass versus medical treatment in morbid obesity. Lancet 1979;2(8155):1255-8.

125. Laws HL, Piantadosi S. Superior gastric reduction procedure for morbid obesity: a prospective, randomized trial. Ann Surg 1981;193(3):334-40.

126. Viddal KO. Intestinal bypass. A randomized, prospective clinical study of end-to-side and end-to-end jejunoileal bypass. Scand J Gastroenterol 1983;18(5):627-34.

127. Naslund I, Wickbom G, Christoffersson E, et al. A prospective randomized comparison of gastric bypass and gastroplasty. Complications and early results. Acta Chir Scand 1986;152:681-9.

128. Sugerman HJ, Starkey JV, Birkenhauer R. A randomized prospective trial of gastric bypass versus vertical banded gastroplasty for morbid obesity and their effects on sweets versus non-sweets eaters. Ann Surg 1987; 205(6):613-24.

129. Hall JC, Watts JM, O'Brien PE, et al. Gastric surgery for morbid obesity. The Adelaide Study. Ann Surg 1990;211(4):419-27.

130. MacLean LD, Rhode BM, Sampalis J, et al. Results of the surgical treatment of obesity. Am J Surg 1993;165(1):155-60; discussion 160-2.

131. Howard L, Malone M, Michalek A, et al. Gastric Bypass and Vertical Banded Gastroplasty- a Prospective Randomized Comparison and 5-Year Follow-up. Obes Surg 1995;5(1):55-60.

132. Buckwalter JA. A prospective comparison of the jejunoileal and gastric bypass operations for morbid obesity. World J Surg 1977;1(6):757-68.

133. Griffen WO Jr, Young VL, Stevenson CC. A prospective comparison of gastric and jejunoileal bypass procedures for morbid obesity. Ann Surg 1977;186(4):500-9.

134. Andersen T, Stokholm KH, Backer OG, et al. Long-term (5-year) results after either horizontal gastroplasty or very- low-calorie diet for morbid obesity. Int J Obes 1988;12(4):277-84.

135. Andersen T, Backer OG, Astrup A, et al. Horizontal or vertical banded gastroplasty after pretreatment with very- low-calorie formula diet: a randomized trial. Int J Obes 1987;11(3):295-304.

136. Lundell L, Ruth M, Olbe L. Vertical banded gastroplasty or gastric banding for morbid obesity: effects on gastro-oesophageal reflux. Eur J Surg 1997;163(7):525-31.

137. Nguyen NT, Goldman C, Rosenquist CJ, et al. Laparoscopic versus open gastric bypass: a randomized study of outcomes, quality of life, and costs. Ann Surg 2001;234(3):279-89; discussion 289-91.

138. Choban PS, Flancbaum L. The effect of Roux limb lengths on outcome after Roux-en-Y gastric bypass: a prospective, randomized clinical trial. Obes Surg 2002;12(4):540-5.

139. Westling A, Gustavsson S. Laparoscopic vs open Roux-en-Y gastric bypass: a prospective, randomized trial. Obes Surg 2001;11(3):284-92.

140. Agren G, Naslund I. A prospective randomized comparison of vertical banded gastroplasty (VBG), loop gastric bypass (GBY), and gastric banding (GB). Int J Obes 1989;13:595.

141. Van Rij AM. Gastric bypass and gastric partitioning in morbid obesity: results of a controlled trial. Aus NZ J Med 1984;14(3 suppl 1):340.

142. VanWoert J, Michalek A, Alger S, et al. A prospective randomized trial (PRT) of gastric bypass (GB) versus vertical banded gatroplasty (VBG) for morbid obesity (MO). Clinical Research 1992;40(2):A642.

143. Naslund I. The size of the gastric outlet and the outcome of surgery for obesity. Acta Chir Scand 1986;152:205-10.

144. Naslund I, Beckman KW. Gastric emptying rate after gastric bypass and gastroplasty. Scand J Gastroenterol 1987;22(2):193-201.

145. Naslund I. Gastric bypass versus gastroplasty. A prospective study of differences in two surgical procedures for morbid obesity. Acta Chir Scand Suppl 1987 ;536:1-60.

146. Naslund I, Hallgren P, Sjostrom L. Fat cell weight and number before and after gastric surgery for morbid obesity in women. Int J Obes 1988;12(3):191-7.

147. Naslund I, Jarnmark I, Andersson H. Dietary intake before and after gastric bypass and gastroplasty for morbid obesity in women. Int J Obes 1988;12(6):503-13.

148. Nilsell K, Thorne A, Sjostedt S, et al. Prospective randomised comparison of adjustable gastric banding and vertical banded gastroplasty for morbid obesity. Eur J Surg 2001;167(7):504-9.

149. Hesse UJ, Berrevoet F, Ceelen W, et al. [Adjustable silicone gastric banding (ASGB, Bioenterics) and the Swedish adjustable gastric banding (SAGB, Obtech) in treatment of morbid obesity]: <Original> Das anpassbare Silicon Gastric Banding (ASGB, Bioenterics) und das Schwedische anpassbare Gastric Banding (SAGB, Obtech) zur Behandlung der morbiden Obesitas. Der Chirurg; Zeitschrift fur alle Gebiete der operativen Medizen 2001;72(1):14-8.

150. Brolin RE, Bradley LJ, Wilson AC, et al. Lipid risk profile and weight stability after gastric restrictive operations for morbid obesity. J Gastrointest Surg 2000;4(5):464-9.

151. van Gemert WG, Adang EM, Greve JW, et al. Quality of life assessment of morbidly obese patients: effect of weight- reducing surgery. Am J Clin Nutr 1998;67(2):197-201.

152. Karason K, Wallentin I, Larsson B, et al. Effects of obesity and weight loss on left ventricular mass and relative wall thickness: survey and intervention study. BMJ 1997;315(7113):912-6.

153. Mason EE, Doherty C, Cullen JJ, et al. Vertical gastroplasty: evolution of vertical banded gastroplasty. World J Surg 1998;22(9):919-24.

154. MacLean L, Rhode B. Does Genetic Predisposition Influence Surgical Results of Operations for Obesity? Obes Surg 1996;6(2):132-137.

155. Matthews BD, Sing RF, DeLegge MH, et al. Initial results with a stapled gastrojejunostomy for the laparoscopic isolated Roux-en-Y gastric bypass. Am J Surg 2000;179(6):476-81.

156. O'Brien PE, Brown WA, Smith A, et al. Prospective study of a laparoscopically placed, adjustable gastric band in the treatment of morbid obesity. Br J Surg 1999;86(1):113-8.

157. Peace K, Dyne J, Russell G, et al. Psychobiological effects of gastric restriction surgery for morbid obesity. N Z Med J 1989;102(862): 76-8.

158. Toppino M, Morino M, Bonnet G, et al. Laparoscopic surgery for morbid obesity: preliminary results from SICE registry (Italian Society of Endoscopic and Minimally Invasive Surgery). Obes Surg 1999;9(1):62-5.

159. Toppino M, Morino M, Capuzzi P, et al. Outcome of vertical banded gastroplasty. Obes Surg 1999;9(1):51-4.

160. Yale CE, Weiler SJ. Weight control after vertical banded gastroplasty for morbid obesity. Am J Surg 1991;162(1):13-8.

161. Aghahosseini H, Roulet D, Cavin R. [Treatment of morbid obesity with adjustable gastric prosthesis: experience and results at the Riviera Hospital in Montreux]. Rev Med Suisse Romande 2001;121(10):709-12.

162. Kalfarentzos F, Dimakopoulos A, Kehagias I, et al. Vertical banded gastroplasty versus standard or distal Roux-en-Y gastric bypass based on specific selection criteria in the morbidly obese: preliminary results. Obes Surg 1999;9(5):433-42.

163. van de Weijgert EJ, Ruseler CH, Elte JW. Long-term follow-up after gastric surgery for morbid obesity: preoperative weight loss improves the long-term control of morbid obesity after vertical banded gastroplasty. Obes Surg 1999;9(5):426-32.

164. Dargent J. Laparoscopic adjustable gastric banding: lessons from the first 500 patients in a single institution. Obes Surg 1999;9(5):446-52.

165. Miller K, Hell E. Laparoscopic adjustable gastric banding: a prospective 4-year follow-up study. Obes Surg 1999;9 (2):183-7.

166. Alden JF. Gastric and jejunoileal bypass. A comparison in the treatment of morbid obesity. Arch Surg 1977;112(7):799-806.

167. Letiexhe MR, Scheen AJ, Gerard PL, et al. Post-gastroplasty recovery of ideal body weight normalizes glucose and insulin metabolism in obese women. J Clin Endocrinol Metab 1995;80:334-369.

168. Melissas J, Christodoulakis M, Spyridakis M, et al. Disorders associated with clinically severe obesity: significant improvement after surgical weight reduction. South Med J 1998;91(12):1143-8.

169. Bloomston M, Zervos EE, Camps MA, et al. Outcome following bariatric surgery in super versus morbidly obese patients: does weight matter? Obes Surg 1997;7(5):414-9.

170. Balsiger BM, Poggio JL, Mai J, et al. Ten and more years after vertical banded gastroplasty as primary operation for morbid obesity. J Gastrointest Surg 2000;4(6):598-605.

171. Davila-Cervantes A, Ganci-Cerrud G, Gamino R, et al. Open vs. laparoscopic vertical banded gastroplasty: a case control study with a 1-year follow-up. Obes Surg 2000;10(5):409-12.

172. Alper D, Ramadan E, Vishne T, et al. Silastic ring vertical gastroplasty- long-term results and complications. Obes Surg 2000;10(3):250-4.

173. Choi Y, Frizzi J, Foley A, et al. Patient satisfaction and results of vertical banded gastroplasty and gastric bypass. Obes Surg 1999;9(1): 33-5.

174. Baltasar A, Bou R, Arlandis F, et al. Vertical banded gastroplasty at more than 5 years. Obes Surg 1998;8(1):29-34.

175. Stoner J, Stoner P, Sytsma J. 42-month preliminary follow-up of the silastic ring vertical banded gastroplasty. Obes Surg 1997;7(6):513-5.

176. Yashkov YI, Timoshin AD, Oppel TA. Vertical banded gastroplasty: first experience in Russia. Obes Surg 1997;7(4):317-20; discussion 321.

177. Goulding ST, Hovell BC. Anaesthetic experience of vertical banded gastroplasty. Br J Anaesth 1995;75(3):301-6.

178. Schauer PR, Ikramuddin S, Gourash W, et al. Outcomes after laparoscopic Roux-en-Y gastric bypass for morbid obesity. Ann Surg 2000;232(4):515-29.

179. Nguyen NT, Ho HS, Palmer LS, et al. A comparison study of laparoscopic versus open gastric bypass for morbid obesity. J Am Coll Surg 2000;191(2):149-55; discussion 155-7.

180. Choban PS, Onyejekwe J, Burge JC, et al. A health status assessment of the impact of weight loss following Roux- en-Y gastric bypass for clinically severe obesity. J Am Coll Surg 1999;188(5):491-7.

181. Doldi SB, Micheletto G, Lattuada E, et al. Adjustable gastric banding: 5-year experience. Obes Surg 2000;10(2):171-3.

182. Freeman JB, Kotlarewsky M, Phoenix C. Weight loss after extended gastric bypass. Obes Surg 1997;7(4):337-44.

183. Crampton NA, Izvornikov V, Stubbs RS. Silastic ring gastric bypass: results in 64 patients. Obes Surg 1997;7(6):489-94.

184. Oh CH, Kim HJ, Oh S. Weight loss following transected gastric bypass with proximal Roux-en-Y. Obes Surg 1997;7(2):142-7; discussion 148.

185. Nowara HA. Egyptian experience in laparoscopic adjustable gastric banding (technique, complications and intermediate results). Obes Surg 2001;11(1):70-5.

186. Wiesner W, Schob O, Hauser RS, et al. Adjustable laparoscopic gastric banding in patients with morbid obesity: radiographic management, results, and postoperative complications. Radiology 2000;216(2):389-94.

187. De Luca M, de Werra C, Formato A, et al. Laparotomic vs laparoscopic lap-band: 4-year results with early and intermediate complications. Obes Surg 2000;10(3):266-8.

188. Suter M, Bettschart V, Giusti V, et al. A 3-year experience with laparoscopic gastric banding for obesity. Surg Endosc 2000;14(6):532-6.

189. Suter M, Giusti V, Heraief E, et al. Early results of laparoscopic gastric banding compared with open vertical banded gastroplasty. Obes Surg 1999;9(4):374-80.

190. Abu-Abeid S, Szold A. Results and complications of laparoscopic adjustable gastric banding: an early and intermediate experience. Obes Surg 1999;9(2):188-90.

191. Forsell P, Hallerback B, Glise H, et al. Complications following Swedish adjustable gastric banding: a long-term follow-up. Obes Surg 1999;9(1):11-6.

192. Doherty C, Maher JW, Heitshusen DS. Prospective investigation of complications, reoperations, and sustained weight loss with an adjustable gastric banding device for treatment of morbid obesity. J Gastrointest Surg 1998;2(1):102-8.

193. Forestieri P, Meucci L, De Luca M, et al. Two years of practice in adjustable silicone gastric banding (LAP- BAND): evaluation of variations of body mass index, percentage ideal body weight and percentage excess body weight. Obes Surg 1998;8(1):49-52.

194. Forsell P, Hellers G. The Swedish Adjustable Gastric Banding (SAGB) for morbid obesity: 9 year experience and a 4-year follow-up of patients operated with a new adjustable band. Obes Surg 1997;7(4):345-51.

195. Horchner R, Tuinebreijer W. Improvement of physical functioning of morbidly obese patients who have undergone a Lap-Band operation: one-year study. Obes Surg 1999;9(4):399-402.

196. Randolph JG, Weintraub WH, Rigg A. Jejunoileal bypass for morbid obesity in adolescents. J Pediatr Surg 1974;9(3):341-5.

197. Rigg CA. Proceedings: Jejunoileal bypass in morbidly obese adolescent. Acta Paediatr Scand Suppl 1975;(256):62-4.

198. White JJ, Cheek D, Haller JA Jr. Small bowel bypass is applicable for adolescents with morbid obesity. Am Surg 1974;40(12):704-8.

199. Pories WJ, Flickinger EG, Meelheim D, et al. The effectiveness of gastric bypass over gastric partition in morbid obesity: consequence of distal gastric and duodenal exclusion. Ann Surg 1982;196(4):389-99.

200. Hess DS, Hess DW. Biliopancreatic diversion with a duodenal switch. Obes Surg 1998;8(3):267-82.

201. Marceau P, Biron S, Bourque RA, et al. Biliopancreatic Diversion with a New Type of Gastrectomy. Obes Surg 1993;3(1):29-35.

202. Mason EE. Vertical banded gastroplasty for obesity. Arch Surg 1982;117(5):701-6.

203. Wittgrove AC, Clark GW. Laparoscopic gastric bypass, Roux-en-Y- 500 patients: technique and results, with 3-60 month follow-up. Obes Surg 2000;10(3):233-9.

204. Higa KD, Boone KB, Ho T. Complications of the laparoscopic Roux-en-Y gastric bypass: 1,040 patients-what have we learned? Obes Surg 2000;10(6):509-13.

205. Higa KD, Boone KB, Ho T, et al. Laparoscopic Roux-en-Y gastric bypass for morbid obesity: technique and preliminary results of our first 400 patients. Arch Surg 2000;135(9):1029-33; discussion 1033-4.

206. Scopinaro N, Gianetta E, Adami GF, et al. Biliopancreatic diversion for obesity at eighteen years. Surgery 1996;119(3):261-8.

207. Belachew M, Legrand M, Vincent V, et al. Laparoscopic adjustable gastric banding. World J Surg 1998;22(9):955-63.

208. Das SK, Roberts SB, Kehayias JJ, et al. Body composition assessment in extreme obesity and after massive weight loss induced by gastric bypass surgery. Am J Physiol Endocrinol Metab 2003;284(6):E1080-8.

209. Tacchino RM, Mancini A, Perrelli M, et al. Body composition and energy expenditure: relationship and changes in obese subjects before and after biliopancreatic diversion. Metabolism 2003;52(5):552-8.

210. Al-Jiffry BO, Shaffer EA, Saccone GT, et al. Changes in gallbladder motility and gallstone formation following laparoscopic gastric banding for morbid obesity. Can J Gastroenterol 2003;17(3):169-74.

211. Weiner R, Blanco-Engert R, Weiner S, et al. Outcome after laparoscopic adjustable gastric banding - 8 years experience. Obes Surg 2003;13(3):427-34.

212. Olbers T, Lonroth H, Fagevik-Olsen M, et al. Laparoscopic gastric bypass: development of technique, respiratory function, and long-term outcome. Obes Surg 2003;13(3):364-70.

213. Mittermair RP, Weiss H, Nehoda H, et al. Laparoscopic Swedish adjustable gastric banding: 6-year follow-up and comparison to other laparoscopic bariatric procedures. Obes Surg 2003;13(3):412-7.

214. Courcoulas A, Perry Y, Buenaventura P, et al. Comparing the outcomes after laparoscopic versus open gastric bypass: a matched paired analysis. Obes Surg 2003;13(3):341-6.

215. Perugini RA, Mason R, Czerniach DR, et al. Predictors of complication and suboptimal weight loss after laparoscopic Roux-en-Y gastric bypass: a series of 188 patients. Arch Surg 2003;138(5):541-5; discussion 545-6.

216. Suter M, Giusti V, Heraief E, et al. Laparoscopic Roux-en-Y gastric bypass: initial 2-year experience. Surg Endosc 2003;17(4):603-9.

217. de Zwaan M, Lancaster KL, Mitchell JE, et al. Health-related quality of life in morbidly obese patients: effect of gastric bypass surgery. Obes Surg 2002;12(6):773-80.

218. Reddy RM, Riker A, Marra D, et al. Open Roux-en-Y gastric bypass for the morbidly obese in the era of laparoscopy. Am J Surg 2002;184(6):611-5; discussion 615-6.

219. Dymek MP, Le Grange D, Neven K, et al. Quality of life after gastric bypass surgery: a cross-sectional study. Obes Res 2002;10(11):1135-42.

220. Papasavas PK, Hayetian FD, Caushaj PF, et al. Outcome analysis of laparoscopic Roux-en-Y gastric bypass for morbid obesity. The first 116 cases. Surg Endosc 2002;16(12):1653-7.

221. Hedenbro JL, Frederiksen SG. Fully stapled gastric bypass with isolated pouch and terminal anastomosis: 1-3 year results. Obes Surg 2002; 12(4):546-50.

222. Pontiroli AE, Pizzocri P, Librenti MC, et al. Laparoscopic adjustable gastric banding for the treatment of morbid (grade 3) obesity and its metabolic complications: a three-year study. J Clin Endocrinol Metab 2002;87(8):3555-61.

223. Feng JJ, Gagner M. Laparoscopic biliopancreatic diversion with duodenal switch. Semin Laparosc Surg 2002;9(2):125-9.

224. Gustavsson S, Westling A. Laparoscopic adjustable gastric banding: complications and side effects responsible for the poor long-term outcome. Semin Laparosc Surg 2002;9(2):115-24.

225. Lujan JA, Hernandez Q, Frutos MD, et al. Laparoscopic gastric bypass in the treatment of morbid obesity. Preliminary results of a new technique. Surg Endosc 2002;16(12):1658-62.

226. Torgerson JS, Sjostrom L. The Swedish Obese Subjects (SOS) study--rationale and results. Int J Obes Relat Metab Disord 2001;25 Suppl 1:S2-4.

227. Alpert MA, Terry BE, Kelly DL. Effect of weight loss on cardiac chamber size, wall thickness and left ventricular function in morbid obesity. Am J Cardiol 1985;55(6):783-6.

228. Alpert MA, Lambert CR, Panayiotou H, et al. Relation of duration of morbid obesity to left ventricular mass, systolic function, and diastolic filling, and effect of weight loss. Am J Cardiol 1995;76(16):1194-7.

229. Sugerman HJ, Baron PL, Fairman RP, Evans CR, Vetrovec GW. Hemodynamic dysfunction in obesity hypoventilation syndrome and the effects of treatment with surgically induced weight loss. Ann Surg. 1988 207:604-13.(Abstract)

230. Karason K, Wallentin I, Larsson B, Sjostrom L. Effects of obesity and weight loss on cardiac function and valvular performance. Obes Res. 1998 6:422-429.(Abstract)

231. Kanoupakis E, Michaloudis D, Fraidakis O, Parthenakis F, Vardas P, Melissas J. Left ventricular function and cardiopulmonary performance following surgical treatment of morbid obesity. Obes Surg. 2001 11:552-558.(Abstract)

232. Smith SC, Edwards CB, Goodman GN. Symptomatic and clinical improvement in morbidly obese patients with gastroesophageal reflux disease following Roux-en-Y gastric bypass. Obes Surg. 1997 7:479-484.(Abstract)

233. Frezza EE, Ikramuddin S, Gourash W, Rakitt T, Kingston A, Luketich J, et al. Symptomatic improvement in gastroesophageal reflux disease (GERD) following laparoscopic Roux-en-Y gastric bypass. Surg Endosc. 2002 16:1027-1031.(Abstract)

234. Macgregor A , Greenberg RA. Effect of surgically induced weight loss on asthma in the morbidly obese. Obes Surg. 1993 3:15-21.(Abstract)

235. Dixon JB, Chapman L, O'Brien P. Marked improvement in asthma after Lap-Band® surgery for morbid obesity. Obes Surg. 1999 9:385-389.(Abstract)

236. Deitel M, Khanna RK, Hagen J, Ilves R. Vertical banded gastroplasty as an antireflux procedure. Am J Surg. 1988 155:512-4.(Abstract)

237. Naslund E, Granstrom L, Melcher A, Stockeld D, Backman L. Gastro-oesophageal reflux before and after vertical banded gastroplasty in the treatment of obesity. Eur J Surg. 1996 162:303-6.(Abstract)

238. Kim CH, Sarr MG. Severe reflux esophagitis after vertical banded gastroplasty for treatment of morbid obesity. Mayo Clin Proc 1992;67(1):33-5.

239. Sugerman HJ, Kellum JM Jr, DeMaria EJ, et al. Conversion of failed or complicated vertical banded gastroplasty to gastric bypass in morbid obesity. Am J Surg 1996;171(2):263-9.

240. Sugerman HJ, Felton WL, Sismanis A, Salvant JB, Kellum JM. Effects of surgically induced weight loss on pseudotumor cerebri in morbid obesity. Neurology. 1995 45:1655-9.(Abstract)

241. Sugerman HJ, Felton WL 3rd, Sismanis A, et al. Gastric surgery for pseudotumor cerebri associated with severe obesity. Ann Surg. 1999 21:682-5.(Abstract)

242. Deitel M, Toan BT, Stone EM, et al. Sex hormone changes accompanying loss of massive excess weight. Gastroenterol Clin N Amer. 1987 16:511-5.(Abstract)

243. Richards DS, Miller DK, Goodman GN. Pregnancy after gastric bypass for morbid obesity. J Reprod Med 1987;32(3):172-6.

244. Marceau P, Biron S, Hould FS, Lebel S, Marceau S, Simard S, et al. Outcome of pregnancies after obesity surgery. In: Guy-Grand B, Ailhaud G. (Eds) Progress in Obesity Research:8. London: John Libbey and Company; 1999. p. 795-802.

245. Dixon JB, Dixon ME, O'Brien PE. Pregnancy after Lap-Band surgery: management of the band to achieve healthy weight outcomes. Obes Surg 2001;11(1):59-65.

246. Friedman D, Cunco S, Valenzano M, Marinari GM, Adami GF, Gianetti E, et al. Pregnancies in an 18-year follow-up after biliopancreatic diversion. Obes Surg. 1995 5:308-313.(Abstract)

247. Wittgrove AC, Jester L, Wittgrove P, Clark GW. Pregnancy following gastric bypass for morbid obesity. Obes Surg. 1998 8:461-464.(Abstract)

248. Bump RC, Sugerman HJ, Fantl JA, et al. Obesity and lower urinary tract function in women: effects of surgically induced weight loss. Am J Obstet Gynecol. 1992 167:392-7.(Abstract)

249. Parvizi J, Trousadale RT, Sarr MG. Total joint arthroplasty in patients surgically treated for morbid obesity. J Arthroplasty. 2000 15:(8)1003-1008.(Abstract)

250. Peltonen M, Lindroos AK, Torgerson JS. Musculoskeletal pain in the obese: a comparison with the general population and long-term changes after conventional and surgical obesity treatment. Pain. 2003 104:549-557.(Abstract)

251. Melissas J, Volakakis E, Hadjipavlou A. Low-back pain in morbidly obese patients and the effect of weight loss following surgery. Obes Surg. 2003 13:389-393.(Abstract)

252. Zacchi P, Mearin F, Humbert P, et al. Effect of obesity on gastroesophageal resistance to flow in man. Dig Dis Sci . 1991 36:1473-80.(Abstract)

253. Ranlov I, Hardt F. Regression of liver steatosis following gastroplasty or gastric bypass for morbid obesity. Degestion. 1990 47:208-214.(Abstract)

254. Sugerman HJ, Sugerman EL, Wolfe L, et al. Risks and benefits of gastric bypass in morbidly obese patients with severe venous stasis disease. Ann Surg 2001;234(1):41-6.

255. Silverman EM, Sapala JA, Appelman HD. Regression of hepatic steatosis in morbidly obese persons after gastric bypass. Am J Clin Pathol . 1995 104:23-31.(Abstract)

256. Luyckx FH, Desaive C, Thiry A, Dewe W, Scheen AJ, Gielen JE, et al. Liver abnormalities in severely obese subjects: effect of drastic weight loss after gastroplasty. Int J Obes Relat Metab Disord . 1998 22:222-226.(Abstract)

257. Kral JG, Thung SN, Biron S, Hould FS, et al. Effects of surgical treatment of the metabolic syndrome on liver fibrosis and cirrhosis. Surgery. 2004 135:48-58.(Abstract)

258. Rand CS, Macgregor A, Hankins G. Gastric bypass surgery for obesity: weight loss, psychosocial outcome, and morbidity one and three years later. South Med J 1986;79(12):1511-4.

259. Kral JG, Sjostrom LV, Sullivan MB. Assessment of quality of life before and after surgery for severe obesity. Am J Clin Nutr 1992;55(2 Suppl):611S-614S.

260. Dixon JB, O'Brien PE. Changes in comorbidities and improvements in quality of life after LAP-BAND placement. Am J Surg 2002;184(6B):51S-54S.

261. Ballantyne GH. Measuring outcomes following bariatric surgery: weight loss parameters, improvement in co-morbid conditions, change in quality of life and patient satisfaction. Obes Surg. 2003 13 :(6)954-64.(Abstract)

262. Herpertz S, Kielmann R, Wolf AM, Langkafel M, Senf W, Hebebrand J. Does obesity surgery improve psychosocial functioning? A systematic review. Int J Obes Relat Metab Disord. 2003 27:(11)1300-14.(Abstract)

263. Guisado JA, Vaz FJ, Alarcon J, Lopez-Ibor JJ Jr, Rubio MA, Gaite L . Psychopathological status and interpersonal functioning following weight loss in morbidly obese patients undergoing bariatric surgery. Obes Surg. 2002 12:(6)835-40.(Abstract)

264. Arcila D, Velazquez D, Gamino R, Sierra M, Salin-Pascual R, Gonzalez-Barranco J, Herrera MF. Quality of life in bariatric surgery. Obes Surg. 2002 12:(5)661-5.(Abstract)

265. Arcila D, Velazquez D, Gamino R, Sierra M, Salin-Pascual R, Gonzalez-Barranco J, Quality of life after gastric bypass surgery: a cross-sectional study. Obes Surg. 2002 10:(11)1135-42.(Abstract)

266. Hell E, Miller KA, Moorehead MK, Norman S. Evaluation of health status and quality of life after bariatric surgery: comparison of standard Roux-en-Y gastric bypass, vertical banded gastroplasty and laparoscopic adjustable silicone gastric banding. Obes Surg. 2000 10:(3)214-9.(Abstract)

267. Weiner R, Datz M, Wagner D, Bockhorn H. Quality-of-life outcome after laparoscopic adjustable gastric banding for morbid obesity. Obes Surg. 1999 9:(6)539-45. (Abstract)

268. Flum D, Dellinger E. The impact of bariatric surgery on patient survival: a population based analysis. American College of Surgeons 89th Annual Clinical Congress Meeting; Chicago, Illinois.

269. Golebiowska M, Chlebna-Sokol D, Kobierska I, et al. [Clinical evaluation of Teronac (mazindol) in the treatment of obesity in children. Part II. Anorectic properties and side effects (author's transl)]. Przegl Lek 1981;38(3):355-8.

270. Golebiowska M, Chlebna-Sokol D, Mastalska A, et al. [The clinical evaluation of teronac (Mazindol) in the treatment of children with obesity. Part I. Effect of the drug on somatic patterns and exercise capacity (author's transl)]. Przegl Lek 1981;38(2):311-4.

271. Wing RR, Epstein LH, Marcus MD, et al. Intermittent low-calorie regimen and booster sessions in the treatment of obesity. Behav Res Ther 1984;22(4):445-9.

272. Berkowitz RI, Wadden TA, Tershakovec AM, et al. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA 2003;289(14):1805-12.

273. Soper RT, Mason EE, Printen KJ, et al. Gastric bypass for morbid obesity in children and adolescents. J Pediatr Surg 1975;10(1):51-8.

274. Anderson AE, Soper RT, Scott DH. Gastric bypass for morbid obesity in children and adolescents. J Pediatr Surg 1980;15(6):876-81.

275. Strauss RS, Bradley LJ, Brolin RE. Gastric bypass surgery in adolescents with morbid obesity. J Pediatr 2001;138(4):499-504.

276. Sugerman HJ, Sugerman EL, DeMaria EJ, et al. Bariatric surgery for severely obese adolescents. J Gastrointest Surg 2003;7(1):102-7; discussion 107-8.

277. Breaux CW. Obesity Surgery in Children. Obes Surg 1995;5(3): 279-284.

278. Dolan K, Creighton L, Hopkins G, et al. Laparoscopic gastric banding in morbidly obese adolescents. Obes Surg 2003;13(1):101-4.

279. Abu-Abeid S, Gavert N, Klausner JM, et al. Bariatric surgery in adolescence. J Pediatr Surg 2003;38(9):1379-82.

280. Peterson CM, Jovanovic-Peterson L. Randomized crossover study of 40% vs. 55% carbohydrate weight loss strategies in women with previous gestational diabetes mellitus and non- diabetic women of 130-200% ideal body weight. J Am Coll Nutr 1995;14(4):369-75.

281. Davis BR, Blaufox MD, Oberman A, et al. Reduction in long-term antihypertensive medication requirements. Effects of weight reduction by dietary intervention in overweight persons with mild hypertension. Arch Intern Med 1993;153(15):1773-82.